Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome

• Sponsor: M.D. Anderson Cancer Center (Other)
• Overall Status: Completed
• CT.gov ID: NCT01893320
• Collaborator: Sunesis Pharmaceuticals (Industry)
• Enrollment: 66
• Location: 1
• Arm: 1
• Actual Duration (Months): 89.8
• Patients Per Site Per Month: 0.7

Study Details

Study Description

Brief Summary

The goal of this clinical research study is to learn if the combination of vosaroxin and decitabine can help to control AML or MDS. The safety of these drugs will also be studied.

Condition or Disease	Intervention/Treatment	Phase
Leukemia	Drug: Vosaroxin; Drug: Decitabine	Phase 1/Phase 2

Detailed Description

Study Groups:

If you are found to be eligible to take part in this study, you will be assigned to a study group based on when you join this study. Up to 4 groups of up to 6 participants will be enrolled in the Phase I portion of the study, and up to 60 participants will be enrolled in Phase II.

If you are enrolled in the Phase I portion, the dose of vosaroxin you receive will depend on when you joined this study. The first group of participants will receive the highest dose level of vosaroxin. If no intolerable side effects are seen, the study will move on to Phase

1. If intolerable side effects are seen, each new group will receive a lower dose of vosaroxin than the group before it until the most tolerable dose is found.

If you are enrolled in the Phase II portion, you will receive vosaroxin at the highest dose that was tolerated in the Phase I portion.

All participants will receive the same dose level of decitabine.

Study Drug Administration:

You will receive the study drugs in cycles. The study cycles will be 4-12 weeks long, depending on if/how the disease responds to the treatment, how your bone marrow reacts to treatment, and what the doctor thinks is in your best interest.

On Days 1-5 of each study cycle, you will receive decitabine by vein over about 1 hour. On Days 1 and 4 of each cycle, you will also receive vosaroxin by vein over 8-10 minutes, before you receive decitabine. Depending on how the disease responds to the study drugs, the number of days you receive the study drug may change. Your doctor will discuss this with you.

The first 2 cycles are called Induction Cycles. All cycles after that are called Consolidation Cycles. All participants will receive Induction Cycle 1. If the study doctor thinks it is needed, you will also receive Induction Cycle 2. If after that the study doctor thinks it is in your best interest, you will receive up to 5 Consolidation Cycles of treatment.

Study Visits:

On Day 1 of each cycle, you will have a physical exam.

Every week, blood (about 1 tablespoon) will be drawn for routine tests. If at any point you appear to have a response to the study drugs, this blood will then be drawn every 1-2 weeks while you are still receiving the study drugs. If your doctor thinks it is needed, more blood may need to be drawn.

On Day 21 of Cycle 1 (+/- 7 days), then every 4 weeks after that, you will have a bone marrow aspiration and/or biopsy to check the status of the disease. If the doctor thinks it is needed, these may be done more or less often, depending on your response to the study drugs.

Length of Study:

You may receive the study drugs for up to 7 cycles. You will be taken off study if the disease gets worse, intolerable side effects occur, or if the study doctor thinks it is in your best interest.

Your participation in the study will be over after the follow-up period.

End-of-Study Visit:

If you are taken off study or if you leave the study early, you will have an end-of-study visit. At this visit:

Blood (about 2-3 teaspoons) will be drawn for routine tests. If the study doctor thinks it is needed, you will have a bone marrow aspiration.

You will then be contacted during a study visit or called and asked about any side effects you may be having 30 days after the end-of-study visit. This call will last about 5 minutes.

Follow-up:

If you do not leave the study early, you will have follow-up visits and calls for up to 5 years after you stop receiving the study drugs.

Every 4-8 weeks, blood (about 1 tablespoon) will be drawn for routine tests. If you cannot return to the clinic, you may have blood drawn at a clinic close to your home.

Every 3-6 months, you will be contacted during a clinic visit and asked how you are doing. If you cannot make it to the clinic for this visit, you will be called. The phone call should last about 5 minutes.

This is an investigational study. Vosaroxin is not FDA approved or commercially available. It is currently being used for research purposes only. Decitabine has been approved by the FDA for the treatment of MDS, which is a precursor of AML, but has not been approved for the treatment of AML. The use of these drugs in combination is investigational. The study doctor can explain how the drugs are designed to work.

Up to 84 patients will take part in this study. All will be enrolled at MD Anderson.

Study Design

• Study Type: Interventional
• Actual Enrollment: 66 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase I/II Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome
• Actual Study Start Date: Jul 18, 2013
• Actual Primary Completion Date: Jan 11, 2021
• Actual Study Completion Date: Jan 11, 2021

Arms and Interventions

Arm

Intervention/Treatment

Experimental: Vosaroxin + Decitabine The first 6 patients on study (first cohort) receive 1 or 2 induction cycles of therapy according to the following starting schedule: Vosaroxin administered intravenously on days 1 and 4 at a dose of 90 mg/m2 in the first cycle (induction 1) for a total dose of 180 mg/m2/cycle in combination with Decitabine at a dose of 20 mg/m2 intravenously daily for 5 consecutive days (Days 1 to 5). Following the phase I portion, patients in phase II receive the following induction: Vosaroxin intravenously on days 1 and 4 at a dose of 70 mg/m2 for a total dose of 140 mg/m2/cycle (days 1 and 4), or the final induction dose (MTD) determined in phase I. Decitabine intravenously at a dose of 20 mg/m2 for 5 consecutive days (days 1 to 5), or the final induction dose (MTD) determined in phase I.

Drug: Vosaroxin; Phase I Starting Dose: 90 mg/m2 by vein on Days 1 and 4 of each cycle. Phase II Starting Dose: 70 mg/m2 by vein on Days 1 and 4 of each cycle, or maximum tolerated dose from Phase I.; Drug: Decitabine; Phase I and II: 20 mg/m2 by vein daily for 5 consecutive days (Days 1 to 5).; Other Names: Dacogen

Outcome Measures

Primary Outcome Measures

1. Maximum Tolerated Dose (MTD) of Vosaroxin in Combination With Decitabine [21 days]

   Maximum tolerated dose (MTD) defined as highest daily oral dose evaluated at which <33% of patients experience a dose limiting toxicity (DLT). A non-hematologic dose-limiting toxicity (DLT) defined as a clinically significant grade 3 or 4 adverse event or abnormal laboratory value (according to CTCAE criteria) assessed by treating physician as related to study drug (and unrelated to disease progression, intercurrent illness, or concomitant medications) occurring during the first 28 days on study. A hematologic DLT defined as severe myelosuppression with a hypoplastic marrow with less than 5% cellularity and no evidence of leukemia 42 days from start of therapy. This will define severe and delayed myelosuppression not related to persistent leukemia and likely related to treatment.

Secondary Outcome Measures

1. Participants With a Response [21 days]

   A Response is defined as: Complete response (CR) + Complete response without platelet recovery (CRp) + CR with insufficient hematological recovery (platelets or neutrophils (CRi). CR is Neutrophil count 2: 1.0 x 10^9/L, platelet count 2: 100 x 10^9/L and bone marrow aspirate and biopsy: S5% blasts. CRp is same as CR but with Platelets < 100 x 10^/L. CRi is same as CR but platelets < 100 x 10(/L or neutrophils < 1 x 10^9.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 60 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

1. Previously untreated AML (>/= 20% blasts). Patients with high-risk MDS (defined as having >/= 10% blasts in the bone marrow) or patients with Chronic Myelomonocytic Leukemia (CMML) (having >/= 10% blasts in the bone marrow) may also be eligible after discussion with Principal Investigator (PI). Prior therapy with hydroxyurea, biological or targeted therapy (e.g. FLT3 inhibitors, other kinase inhibitors), or hematopoietic growth factors is allowed, however prior therapy with chemotherapy agents for the disease under study is not allowed. Patients may have received one dose of cytarabine (up to 2 g/m2) administered at presentation for control of hyperleucocytosis. For patients with prior MDS or CMML who transformed to AML, therapy received for MDS is not considered as prior therapy for AML.

2. Age >/= 60 years and not candidates for conventional cytotoxic chemotherapy or refuse it; OR patients below the age of 60 years who are considered unfit and/or unable to tolerate standard chemotherapy at the discretion of the treating physician or the principal investigator. "

3. Eastern Cooperative Oncology Group performance status </= 2.

4. Adequate hepatic (serum total bilirubin </= 1.5 x upper limit normal (ULN), alanine aminotransferase and/or aspartate transaminase </= 2.5 x ULN) and renal function (creatinine </= 2.0 mg/dL).

5. Left ventricular ejection fraction (LVEF) at least 40% by multiple gated acquisition (MUGA) scan or echocardiogram (ECHO)

6. Patients must be willing and able to review, understand, and provide written consent before starting therapy.

7. Females must be surgically or biologically sterile or postmenopausal (amenorrheic for at least 12 months) or if of childbearing potential, must have a negative serum pregnancy test within 14 days before the start of the treatment. Women of childbearing potential may have a urine pregnancy test, instead of a serum pregnancy test. If either the serum or urine pregnancy test is equivocally negative the patient will be eligible for the protocol. Women of childbearing potential must agree to use an adequate method of contraception during the study until 30 days after the last treatment. Males must be surgically or biologically sterile or agree to use an adequate method of contraception during the study until 30 days after the last treatment.

Exclusion Criteria:

1. New York Heart Association class III or IV heart disease, active ischemia or any other uncontrolled cardiac condition such as active angina pectoris, clinically significant cardiac arrhythmia that requires therapy in the opinion of the treating physician or PI, uncontrolled hypertension (blood pressure > 160 systolic and > 110 diastolic not responsive to antihypertensive medication), uncontrolled diabetes mellitus in the opinion of the treating physician or PI, or uncontrolled congestive heart failure in the opinion of the treating physician or PI.

2. Myocardial infarction in the previous 12 weeks (from the start of treatment).

3. Active and uncontrolled disease/infection as judged by the treating physician

4. Pregnant or breastfeeding

5. Known Human Immunodeficiency Virus seropositivity

6. Any other medical, psychological, or social condition that may interfere with study participation or compliance, or compromise patient safety in the opinion of the investigator or medical monitor

7. Acute promyelocytic leukemia (APL).

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	University of Texas MD Anderson Cancer Center	Houston	Texas	United States	77030

Sponsors and Collaborators

• M.D. Anderson Cancer Center
• Sunesis Pharmaceuticals

Investigators

• Principal Investigator: Naval Daver, MD, M.D. Anderson Cancer Center

Study Documents (Full-Text)

• Study Protocol and Statistical Analysis Plan - Oct 2, 2019

More Information

Additional Information:

• University of Texas MD Anderson Cancer Center Website

Publications

None provided.

• Responsible Party: M.D. Anderson Cancer Center
• ClinicalTrials.gov Identifier: NCT01893320
• Other Study ID Numbers: 2013-0099; NCI-2013-01665
• First Posted: Jul 9, 2013
• Last Update Posted: Feb 9, 2022
• Last Verified: Jan 1, 2022

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Keywords provided by M.D. Anderson Cancer Center: Leukemia; Acute Myeloid Leukemia; AML; High-risk Myelodysplastic Syndrome; MDS; Chronic Myelomonocytic Leukemia; CMM; Maximum tolerated dose; MTD; Vosaroxin; Decitabine; Dacogen
• Additional relevant MeSH terms: Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Preleukemia; Myelodysplastic Syndromes; Decitabine

Study Results

Participant Flow

Recruitment Details	Recruitment Period: July 2013 to June 2016

Arm/Group Title	Phase I MTD Vosaroxin	Vosaroxin + Decitabine
Arm/Group Description	The first 7 patients on study (first cohort) receive 1 or 2 induction cycles of therapy according to the following starting schedule: Vosaroxin administered intravenously on days 1 and 4 at a dose of 90 mg/m2 in the first cycle (induction 1) for a total dose of 180 mg/m2/cycle in combination with Decitabine at a dose of 20 mg/m2 intravenously daily for 5 consecutive days (Days 1 to 5).	The first 7 patients on study (first cohort) receive 1 or 2 induction cycles of therapy according to the following starting schedule: Vosaroxin administered intravenously on days 1 and 4 at a dose of 90 mg/m2 in the first cycle (induction 1) for a total dose of 180 mg/m2/cycle in combination with Decitabine at a dose of 20 mg/m2 intravenously daily for 5 consecutive days (Days 1 to 5). Following the phase I portion, patients in phase II receive the following induction: Vosaroxin intravenously on days 1 and 4 at a dose of 70 mg/m2 for a total dose of 140 mg/m2/cycle (days 1 and 4), or the final induction dose (MTD) determined in phase I. Decitabine intravenously at a dose of 20 mg/m2 for 5 consecutive days (days 1 to 5), or the final induction dose (MTD) determined in phase I. Vosaroxin: Phase I Starting Dose: 90 mg/m2 by vein on Days 1 and 4 of each cycle. Phase II Starting Dose: 70 mg/m2 by vein on Days 1 and 4 of each cycle, or maximum tolerated dose from Phase I. Decitabine: Phase I and II: 20 mg/m2 by vein daily for 5 consecutive days (Days 1 to 5).
Period Title: Overall Study
STARTED	7	59
COMPLETED	7	59
NOT COMPLETED	0	0

Baseline Characteristics

Arm/Group Title	Phase I MTD Vosaroxin	Vosaroxin + Decitabine	Total
Arm/Group Description	The first 7 patients on study (first cohort) receive 1 or 2 induction cycles of therapy according to the following starting schedule: Vosaroxin administered intravenously on days 1 and 4 at a dose of 90 mg/m2 in the first cycle (induction 1) for a total dose of 180 mg/m2/cycle in combination with Decitabine at a dose of 20 mg/m2 intravenously daily for 5 consecutive days (Days 1 to 5).	The first 7 patients on study (first cohort) receive 1 or 2 induction cycles of therapy according to the following starting schedule: Vosaroxin administered intravenously on days 1 and 4 at a dose of 90 mg/m2 in the first cycle (induction 1) for a total dose of 180 mg/m2/cycle in combination with Decitabine at a dose of 20 mg/m2 intravenously daily for 5 consecutive days (Days 1 to 5). Following the phase I portion, patients in phase II receive the following induction: Vosaroxin intravenously on days 1 and 4 at a dose of 70 mg/m2 for a total dose of 140 mg/m2/cycle (days 1 and 4), or the final induction dose (MTD) determined in phase I. Decitabine intravenously at a dose of 20 mg/m2 for 5 consecutive days (days 1 to 5), or the final induction dose (MTD) determined in phase I. Vosaroxin: Phase I Starting Dose: 90 mg/m2 by vein on Days 1 and 4 of each cycle. Phase II Starting Dose: 70 mg/m2 by vein on Days 1 and 4 of each cycle, or maximum tolerated dose from Phase I. Decitabine: Phase I and II: 20 mg/m2 by vein daily for 5 consecutive days (Days 1 to 5).	Total of all reporting groups
Overall Participants	7	59	66
Age (Count of Participants)
<=18 years	0 0%	0 0%	0 0%
Between 18 and 65 years	2 28.6%	9 15.3%	11 16.7%
>=65 years	5 71.4%	50 84.7%	55 83.3%
Age (years) [Median (Full Range) ]
Median (Full Range) [years]	69	69	69
Sex: Female, Male (Count of Participants)
Female	0 0%	24 40.7%	24 36.4%
Male	7 100%	35 59.3%	42 63.6%
Race (NIH/OMB) (Count of Participants)
American Indian or Alaska Native	0 0%	0 0%	0 0%
Asian	0 0%	3 5.1%	3 4.5%
Native Hawaiian or Other Pacific Islander	0 0%	0 0%	0 0%
Black or African American	0 0%	3 5.1%	3 4.5%
White	7 100%	49 83.1%	56 84.8%
More than one race	0 0%	0 0%	0 0%
Unknown or Not Reported	0 0%	4 6.8%	4 6.1%
Region of Enrollment (participants) [Number]
United States	7 100%	59 100%	66 100%

Outcome Measures

1. Primary Outcome

Title	Maximum Tolerated Dose (MTD) of Vosaroxin in Combination With Decitabine
Description	Maximum tolerated dose (MTD) defined as highest daily oral dose evaluated at which <33% of patients experience a dose limiting toxicity (DLT). A non-hematologic dose-limiting toxicity (DLT) defined as a clinically significant grade 3 or 4 adverse event or abnormal laboratory value (according to CTCAE criteria) assessed by treating physician as related to study drug (and unrelated to disease progression, intercurrent illness, or concomitant medications) occurring during the first 28 days on study. A hematologic DLT defined as severe myelosuppression with a hypoplastic marrow with less than 5% cellularity and no evidence of leukemia 42 days from start of therapy. This will define severe and delayed myelosuppression not related to persistent leukemia and likely related to treatment.
Time Frame	21 days

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Phase I MTD Vosaroxin
Arm/Group Description	The first 7 patients on study (first cohort) receive 1 or 2 induction cycles of therapy according to the following starting schedule: Vosaroxin administered intravenously on days 1 and 4 at a dose of 90 mg/m2 in the first cycle (induction 1) for a total dose of 180 mg/m2/cycle in combination with Decitabine at a dose of 20 mg/m2 intravenously daily for 5 consecutive days (Days 1 to 5).
Measure Participants	7
Number [Mg/m^2]	70

2. Secondary Outcome

Title	Participants With a Response
Description	A Response is defined as: Complete response (CR) + Complete response without platelet recovery (CRp) + CR with insufficient hematological recovery (platelets or neutrophils (CRi). CR is Neutrophil count 2: 1.0 x 10^9/L, platelet count 2: 100 x 10^9/L and bone marrow aspirate and biopsy: S5% blasts. CRp is same as CR but with Platelets < 100 x 10^/L. CRi is same as CR but platelets < 100 x 10(/L or neutrophils < 1 x 10^9.
Time Frame	21 days

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Phase I MTD Vosaroxin	Vosaroxin + Decitabine
Arm/Group Description	The first 7 patients on study (first cohort) receive 1 or 2 induction cycles of therapy according to the following starting schedule: Vosaroxin administered intravenously on days 1 and 4 at a dose of 90 mg/m2 in the first cycle (induction 1) for a total dose of 180 mg/m2/cycle in combination with Decitabine at a dose of 20 mg/m2 intravenously daily for 5 consecutive days (Days 1 to 5).	The first 7 patients on study (first cohort) receive 1 or 2 induction cycles of therapy according to the following starting schedule: Vosaroxin administered intravenously on days 1 and 4 at a dose of 90 mg/m2 in the first cycle (induction 1) for a total dose of 180 mg/m2/cycle in combination with Decitabine at a dose of 20 mg/m2 intravenously daily for 5 consecutive days (Days 1 to 5). Following the phase I portion, patients in phase II receive the following induction: Vosaroxin intravenously on days 1 and 4 at a dose of 70 mg/m2 for a total dose of 140 mg/m2/cycle (days 1 and 4), or the final induction dose (MTD) determined in phase I. Decitabine intravenously at a dose of 20 mg/m2 for 5 consecutive days (days 1 to 5), or the final induction dose (MTD) determined in phase I. Vosaroxin: Phase I Starting Dose: 90 mg/m2 by vein on Days 1 and 4 of each cycle. Phase II Starting Dose: 70 mg/m2 by vein on Days 1 and 4 of each cycle, or maximum tolerated dose from Phase I. Decitabine: Phase I and II: 20 mg/m2 by vein daily for 5 consecutive days (Days 1 to 5).
Measure Participants	7	59
Count of Participants [Participants]	7 100%	42 71.2%

Adverse Events

Time Frame	Up to 2 years 11 months
Arm/Group Title	Phase I MTD Vosaroxin		Vasoroxin + Decitabine
Arm/Group Description	The first 7 patients on study (first cohort) receive 1 or 2 induction cycles of therapy according to the following starting schedule: Vosaroxin administered intravenously on days 1 and 4 at a dose of 90 mg/m2 in the first cycle (induction 1) for a total dose of 180 mg/m2/cycle in combination with Decitabine at a dose of 20 mg/m2 intravenously daily for 5 consecutive days (Days 1 to 5).		The first 7 patients on study (first cohort) receive 1 or 2 induction cycles of therapy according to the following starting schedule: Vosaroxin administered intravenously on days 1 and 4 at a dose of 90 mg/m2 in the first cycle (induction 1) for a total dose of 180 mg/m2/cycle in combination with Decitabine at a dose of 20 mg/m2 intravenously daily for 5 consecutive days (Days 1 to 5). Following the phase I portion, patients in phase II receive the following induction: Vosaroxin intravenously on days 1 and 4 at a dose of 70 mg/m2 for a total dose of 140 mg/m2/cycle (days 1 and 4), or the final induction dose (MTD) determined in phase I. Decitabine intravenously at a dose of 20 mg/m2 for 5 consecutive days (days 1 to 5), or the final induction dose (MTD) determined in phase I. Vosaroxin: Phase I Starting Dose: 90 mg/m2 by vein on Days 1 and 4 of each cycle. Phase II Starting Dose: 70 mg/m2 by vein on Days 1 and 4 of each cycle, or maximum tolerated dose from Phase I. Decitabine: Phase I and II: 20 mg/m2 by vein daily for 5 consecutive days (Days 1 to 5).
All Cause Mortality
	Phase I MTD Vosaroxin		Vasoroxin + Decitabine
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	0/7 (0%)		7/59 (11.9%)
Serious Adverse Events
	Phase I MTD Vosaroxin		Vasoroxin + Decitabine
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	6/7 (85.7%)		48/59 (81.4%)
Blood and lymphatic system disorders
Febrile Neutropenia	3/7 (42.9%)	8	18/59 (30.5%)	23
Cardiac disorders
Myocardial Infarction	1/7 (14.3%)	1	0/59 (0%)	0
Gastrointestinal disorders
Abdominal Pain	0/7 (0%)	0	1/59 (1.7%)	1
Gastrointestinal Disorders - Other	0/7 (0%)	0	1/59 (1.7%)	1
Ileus	0/7 (0%)	0	1/59 (1.7%)	1
Mucositis Oral	2/7 (28.6%)	2	4/59 (6.8%)	4
Nausea	0/7 (0%)	0	1/59 (1.7%)	1
Proctitis	0/7 (0%)	0	1/59 (1.7%)	1
Rectal Hemorrhage	0/7 (0%)	0	2/59 (3.4%)	2
General disorders
Back Pain	0/7 (0%)	0	1/59 (1.7%)	1
Edema Face	0/7 (0%)	0	1/59 (1.7%)	1
Fatigue	0/7 (0%)	0	1/59 (1.7%)	1
Generalized Weakness	0/7 (0%)	0	1/59 (1.7%)	1
Multi-Organ Failure	0/7 (0%)	0	1/59 (1.7%)	1
Non-Cardiac Chest Pain	0/7 (0%)	0	1/59 (1.7%)	1
Infections and infestations
Bone Infection	0/7 (0%)	0	1/59 (1.7%)	1
Catheter Related Infection	0/7 (0%)	0	3/59 (5.1%)	3
Enterocolitis Infection	0/7 (0%)	0	1/59 (1.7%)	1
Infection	0/7 (0%)	0	8/59 (13.6%)	10
Lung Infection	2/7 (28.6%)	2	13/59 (22%)	17
Pharyngitis	0/7 (0%)	0	2/59 (3.4%)	2
Sepsis	1/7 (14.3%)	1	11/59 (18.6%)	12
Skin Infection	0/7 (0%)	0	1/59 (1.7%)	1
Soft Tissue Infection	0/7 (0%)	0	1/59 (1.7%)	1
Urinary Tract Infection	1/7 (14.3%)	1	2/59 (3.4%)	2
Investigations
Blood Bilirubin Increased	0/7 (0%)	0	2/59 (3.4%)	2
Metabolism and nutrition disorders
Dehydration	1/7 (14.3%)	1	2/59 (3.4%)	2
Hypomagnesemia	1/7 (14.3%)	1	0/59 (0%)	0
Musculoskeletal and connective tissue disorders
Bone Pain	1/7 (14.3%)	1	1/59 (1.7%)	1
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neoplasms benign, malignant and unspecified	0/7 (0%)	0	1/59 (1.7%)	1
Nervous system disorders
Intracranial Hemorrhage	0/7 (0%)	0	1/59 (1.7%)	1
Stroke	0/7 (0%)	0	1/59 (1.7%)	1
Syncope	0/7 (0%)	0	1/59 (1.7%)	1
Psychiatric disorders
Delirium	0/7 (0%)	0	1/59 (1.7%)	1
Renal and urinary disorders
Acute Kidney Injury	0/7 (0%)	0	1/59 (1.7%)	1
Renal Calculi	0/7 (0%)	0	1/59 (1.7%)	1
Respiratory, thoracic and mediastinal disorders
Respiratory Failure	0/7 (0%)	0	3/59 (5.1%)	3
Respiratory, thoracic and mediastinal disorders	0/7 (0%)	0	1/59 (1.7%)	1
Other (Not Including Serious) Adverse Events
	Phase I MTD Vosaroxin		Vasoroxin + Decitabine
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	2/7 (28.6%)		19/59 (32.2%)
Cardiac disorders
Heart Failure	0/7 (0%)	0	1/59 (1.7%)	1
Ear and labyrinth disorders
Hearing Impaired	0/7 (0%)	0	1/59 (1.7%)	1
Eye disorders
Conjunctivitis	0/7 (0%)	0	1/59 (1.7%)	1
Gastrointestinal disorders
Ileus	0/7 (0%)	0	1/59 (1.7%)	1
Toothache	0/7 (0%)	0	1/59 (1.7%)	1
General disorders
Gait disturbance	0/7 (0%)	0	2/59 (3.4%)	2
Infections and infestations
Infection	0/7 (0%)	0	1/59 (1.7%)	1
Soft Tissue Infection	0/7 (0%)	0	1/59 (1.7%)	1
Injury, poisoning and procedural complications
Fall	0/7 (0%)	0	3/59 (5.1%)	3
Wound Complication	0/7 (0%)	0	1/59 (1.7%)	1
Investigations
Alanine Aminotransferase Increased	0/7 (0%)	0	1/59 (1.7%)	1
Aspartate Aminotransferase Increase	0/7 (0%)	0	1/59 (1.7%)	1
Blood Bilirubin Increase	1/7 (14.3%)	1	2/59 (3.4%)	2
Metabolism and nutrition disorders
Hyperglycemia	0/7 (0%)	0	1/59 (1.7%)	1
Hyperkalemia	0/7 (0%)	0	1/59 (1.7%)	1
Hypernatremia	0/7 (0%)	0	1/59 (1.7%)	1
Hypocalcemia	0/7 (0%)	0	1/59 (1.7%)	1
Hypokalemia	0/7 (0%)	0	4/59 (6.8%)	5
Hyponatremia	0/7 (0%)	0	1/59 (1.7%)	1
Hypophosphatemia	0/7 (0%)	0	1/59 (1.7%)	1
Musculoskeletal and connective tissue disorders
Arthritis	0/7 (0%)	0	1/59 (1.7%)	1
Nervous system disorders
Dysartharia	0/7 (0%)	0	1/59 (1.7%)	1
Hallucinations	0/7 (0%)	0	1/59 (1.7%)	1
Seizure	0/7 (0%)	0	1/59 (1.7%)	1
Renal and urinary disorders
Acute Kidney Injury	1/7 (14.3%)	1	1/59 (1.7%)	1
Urine discoloration	0/7 (0%)	0	1/59 (1.7%)	1
Respiratory, thoracic and mediastinal disorders
Hoarsness	0/7 (0%)	0	1/59 (1.7%)	1
Postnasal drip	0/7 (0%)	0	1/59 (1.7%)	1
Skin and subcutaneous tissue disorders
Burn	0/7 (0%)	0	1/59 (1.7%)	1
Erythema multiforme	0/7 (0%)	0	1/59 (1.7%)	1

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

All Principal Investigators ARE employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.